Em­maus re­scinds EU mar­ket­ing ap­pli­ca­tion, fol­low­ing neg­a­tive re­view

Two years ago, Em­maus Life Sci­ences se­cured FDA ap­proval for its sick­le cell dis­ease (SCD) ther­a­py — mark­ing the first new ap­proval for pa­tients af­fect­ed by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER